

Evaluating the influence of abnormalities in immunity due to an extreme reaction to an infection (sepsis) on antibiotic use in critically ill patients

Submission date 08/12/2020	Recruitment status No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input checked="" type="checkbox"/> Protocol
Registration date 05/01/2021	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 27/04/2023	Condition category Infections and Infestations	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Sepsis is a life threatening condition due to infection in which the immune system has an abnormally over-active and under-active response (immunosuppression). Patients who have pronounced immunosuppression have a higher risk of getting further infections while in hospital, have a longer stay in hospital and even have a higher rate of death.

Patients with sepsis require treatment with antibiotics and the length of antibiotic course is often fixed. A trial (called ADAPT-sepsis <https://www.isrctn.com/ISRCTN47473244>) is currently underway to see whether two markers that can be measured in blood or 'biomarkers' (called procalcitonin (PCT) and c-reactive protein (CRP)), can reduce antibiotic use in patients with sepsis. The purpose is to see if using these biomarkers will reduce antibiotic use. These biomarkers are generally high at the start of the illness and when they fall to a certain level, the clinician will be advised to stop antibiotics.

Who can participate?

Patients enrolled in the ADAPT-sepsis trial.

What does the study involve?

As an observational study, participants will have four blood samples taken over a one-week period. These samples will be sent to a central laboratory for testing of white cell markers which will give a picture of immune function of patients. This observational study is a sub-study of an ongoing randomised controlled trial (ISRCTN47473244) and so all other procedures such as consent and clinical data collection will occur as part of the main trial.

What are the possible benefits and risks of participating?

Individual patients are unlikely to benefit from participating in this study. The amount of additional blood taken is small and is taken in most cases from an arterial or venous tube at the same time as blood required for routine clinical care. In exceptional cases, blood sampling is

from a vein using a needle. There may be a sharp scratch when the needle is inserted and possible bruising from the area from which the blood is taken.

Where is the study run from?

The Newcastle upon Tyne Hospitals NHS Foundation Trust (UK)

When is the study starting and how long is it expected to run for?

August 2020 to July 2024

Who is funding the study?

National Institute for Health Research (NIHR) (UK)

Who is the main contact?

Dr Tom Ewen, Tom.Ewen@newcastle.ac.uk

Dr Thomas Hellyer, thomas.hellyer@newcastle.ac.uk

Study website

<https://warwick.ac.uk/fac/sci/med/research/ctu/trials/adaptsepsis/>

Contact information

Type(s)

Public

Contact name

Dr Tom Ewen

Contact details

Research Project Managers

Faculty of Medical Sciences

Newcastle University

Newcastle upon Tyne

United Kingdom

NE2 4HH

+44 (0)191 208 5644

Tom.Ewen@newcastle.ac.uk

Type(s)

Scientific

Contact name

Dr Thomas Hellyer

ORCID ID

<http://orcid.org/0000-0001-5346-7411>

Contact details

Institute of Cellular Medicine

Newcastle University

Medical School

Framlington Place

Newcastle upon Tyne
United Kingdom
NE2 4HH
+44 (0)191 20 82422
thomas.hellyer@newcastle.ac.uk

Additional identifiers

EudraCT/CTIS number

Nil known

IRAS number

209815

ClinicalTrials.gov number

Nil known

Secondary identifying numbers

R121074, IRAS 209815, CPMS 45252, NIHR128374

Study information

Scientific Title

The Role of Immunosuppression in an antibiotic Stewardship intervention and its association with Clinical outcomes and antibiotic use: RISC-sepsis

Acronym

RISC-sepsis

Study objectives

As a mechanistic study embedded within a biomarker-guided antibiotic duration trial, this study will determine whether patients with sepsis-induced immunosuppression have prolonged duration of antibiotics and different trial outcomes.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 21/10/2020, South Central - Oxford C Research Ethics Committee (Level 3, Block B, Whitefriars Building, Lewins Mead, Bristol, BS1 2NT, UK; Tel: +44 (0)207 104 8379; oxfordc.rec@hra.nhs.uk), ref: 17/SC/0434

Study design

Prospective multi-centre exploratory cohort observational study embedded within the ADAPT-sepsis trial

Primary study design

Observational

Secondary study design

Clinical laboratory

Study setting(s)

Hospital

Study type(s)

Other

Participant information sheet

<https://warwick.ac.uk/fac/sci/med/research/ctu/trials/adaptsepsis/health/isf/>

Health condition(s) or problem(s) studied

Hospitalised adults who have been commenced on intravenous antibiotics for sepsis

Interventions

As an observational study, participant involvement will be limited to sampling of blood at 4 time points over a one-week period. Blood samples will be transferred to a central laboratory. Immune phenotype will be performed by measuring cellular surface markers by fluorescence-based flow cytometry. These markers will include but not limited to, HLA-DR, CD88, PD-1 and regulatory T cells.

ADAPT-sepsis study registration: <https://www.isrctn.com/ISRCTN47473244>

Intervention Type

Other

Primary outcome measure

Immune phenotype measured using fluorescence-based flow cytometry of blood samples taken at ...

1. Monocyte HLA-DR
2. Neutrophil CD88
3. T cell, monocyte and neutrophil CD279
4. Percentage of regulatory T cells

Secondary outcome measures

Measured using patient records:

1. Total duration of antibiotic treatment to 28 days following randomisation (superiority) measured in days (24-hour time periods)
2. Antibiotic dose, measured as Defined Daily Dose to 28 days
3. Unscheduled care escalation/re-admission
4. Infection relapse/recurrence requiring further antibiotic treatment
5. Super-infection, defined as new infection at a different anatomical site
6. Suspected antibiotic adverse reactions
7. Time to 'fit' for hospital discharge

Overall study start date

01/08/2020

Completion date

31/07/2024

Eligibility

Key inclusion criteria

Patients enrolled in the ADAPT-sepsis trial. Patients are eligible if:

1. Hospitalised adult patients at least 18 years of age
2. Up to 24 hours of initiation of empiric intravenous antibiotic treatments for suspicion of sepsis
3. Likely to remain hospitalised and receiving intravenous antibiotic treatment for at least the next 72 hours
4. Requirement for critical care

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

198

Total final enrolment

198

Key exclusion criteria

1. More than 24 hours since receiving first empiric intravenous antibiotic treatments for a suspicion of sepsis
2. Prolonged (greater than 21 days) antimicrobial therapy mandated (e.g. for endocarditis, cerebral/hepatic abscess, tuberculosis, osteomyelitis)
3. Severely immunocompromised (e.g. neutropenia, less than 500 neutrophils/microlitre)
4. All treatment for suspected sepsis likely to be stopped within 24 hours of its initiation because of futility
5. Consent declined
6. Previously enrolled in ADAPT-sepsis

Date of first enrolment

01/04/2022

Date of final enrolment

21/04/2023

Locations

Countries of recruitment

England

United Kingdom

Study participating centre

Royal Victoria Infirmary

The Newcastle upon Tyne Hospitals NHS Foundation Trust
Queen Victoria Road
Newcastle upon Tyne
United Kingdom
NE1 4LP

Sponsor information

Organisation

University of Manchester

Sponsor details

Directorate of Research and Business Engagement
Christie Building
Manchester
England
United Kingdom
M13 9PL
+44 (0)161 275 2725
clinicaltrials@manchester.ac.uk

Sponsor type

University/education

Website

<https://www.manchester.ac.uk/>

ROR

<https://ror.org/027m9bs27>

Funder(s)

Funder type

Government

Funder Name

National Institute for Health Research

Alternative Name(s)

National Institute for Health Research, NIHR Research, NIHRresearch, NIHR - National Institute for Health Research, NIHR (The National Institute for Health and Care Research), NIHR

Funding Body Type

Government organisation

Funding Body Subtype

National government

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Planned publication in a high-impact peer-reviewed journal.

Intention to publish date

31/07/2025

Individual participant data (IPD) sharing plan

Current IPD sharing statement as of 20/04/2021:

Following publication of the study's findings, publicly available summary data of immune phenotyping datasets will be made findable through those publications. Access to the full dataset will be made available via request to the chief investigator, Dr Tom Hellyer (thomas.hellyer@newcastle.ac.uk). Access requests will be considered in accordance with Newcastle University Data Sharing Policies and all external users submitting applications for access to data will require data sharing agreements in keeping with the NIHR requirements. The data use agreement must detail the agreed use and appropriate management of the data and include a requirement for recognition of the contribution of the researchers who generated the data and the original funder.

Patient will consent to archiving of data and data sharing limited to researchers for future research. All data will be available for peer review at the point of deposition and publication, and will be archived for a minimum of 10 years after publication.

Previous IPD sharing statement:

All data generated or analysed during this study will be included in the subsequent results publication.

IPD sharing plan summary

Available on request

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Protocol article		09/12/2022	16/12/2022	Yes	No
HRA research summary			28/06/2023	No	No